CorMedix

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CorMedix progresses on DefenCath NDA resubmission amidst financial challenges

CorMedix is actively working towards resubmitting the DefenCath NDA and preparing for commercialization, despite facing challenges in FDA interactions and financial performance. The company's strong cash position provides operational flexibility and readiness for potential NDA approval, with opportunities for growth in addressing CRBSIs.

CorMedix plans DefenCath launch in 2024, strengthens IP protection

CorMedix is strategically positioning for the potential commercial launch of DefenCath in early 2024, pending FDA approvals.
Despite financial challenges in Q1 2023, the company's strong IP protection and engagement strategies offer growth opportunities.

CorMedix reports key milestones and strong financial position in Q2 2023

CorMedix's Q2 2023 Earnings Call highlighted key achievements, financial updates, and strategic initiatives, showcasing the company's progress and readiness for upcoming milestones.
Despite facing challenges such as a net loss increase and operational complexities, CorMedix's strong financial position, milestones achieved, and strategic focus position it well for future growth and success.
With opportunities to drive commercialization, expand market access, and establish partnerships, CorMedix is poised to capitalize on its strengths and navigate challenges effectively in the evolving healthcare landscape.

CorMedix prepares for DefenCath launch with strong cash position

CorMedix is strategically positioned for the commercial launch of DefenCath, with a strong cash position and ongoing discussions with regulatory bodies for reimbursement. Despite challenges in operating expenses and net loss in Q3 2023, the company's focus on key catalysts in 2024 presents significant growth opportunities.

CorMedix reports Q4 loss, eyes profitability in 2024 amid milestones

CorMedix faces challenges with rising operating expenses impacting profitability but has achieved key milestones and optimized field operations.
Opportunities lie in label expansions, reimbursement approvals, and gradual market penetration strategies.
Maintaining financial discipline while pursuing growth initiatives will be crucial for CorMedix's success.
Overall, CorMedix's strategic focus on commercial launch and potential expansions sets the stage for future growth.

CorMedix progresses with DefenCath launch, eyes profitability by 2024

CorMedix is making strides with DefenCath's commercial launch and engaging key dialysis providers for procurement contracts.
Financially, the company aims for breakeven by end of 2024, supported by a credit facility and ample cash reserves.
Challenges include managing operating expenses and evaluating potential M&A opportunities for strategic growth.
Opportunities lie in outpatient commercialization, label expansion, and demonstrating DefenCath's value through real-world evidence studies.

CorMedix sees strong sales growth with DefenCath launch success

CorMedix's successful DefenCath launch generated $5.2 million in sales, with inpatient sales expected to rise in Q4. The company is focused on securing reimbursement from Medicare Advantage plans and funding clinical initiatives without significant dilution.

CorMedix reports strong Q3 results, eyes FDA approvals for growth

CorMedix's Q3 performance exceeded expectations, showing revenue growth and operational improvements.
While facing challenges in revenue guidance variability and increased expenses, the company is poised for EBITDA positivity in Q4.
Strengths lie in product acceptance, market expansion, and commitment to research, with opportunities in new agreements, studies, and FDA approvals.
Careful financial management and successful regulatory milestones will be key to capitalizing on growth opportunities and maintaining profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

BERKELEY HEIGHTS, N.J., Aug.  03, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Monday, August 10, and will host a corporate update conference call at 4:30pm Eastern Time.

CorMedix Inc. to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 10

BERKELEY HEIGHTS, N.J., July  28, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD) (the “Company”), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it has priced its underwritten public offering of 4,444,444 shares of its common stock at $4.50 per share for total gross proceeds, before underwriting commissions and estimated expenses, of approximately $20 million. In connection with the offering, the Company granted the underwriters a 30-day option to purchase up to an additional 666,666 shares of common stock.  The offering is expected to close on July 30, 2020, subject to customary closing conditions.    

CorMedix Announces Pricing of $20M Public Offering of Common Stock

CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

CorMedix (CRMD) Jumps: Stock Rises 7.5%

Priority Review of NDA Requested Priority Review of NDA Requested

CorMedix Inc. Reports Submission of Defencath™ New Drug Application

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CorMedix (CRMD) Moves to Buy: Rationale Behind the Upgrade

CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q1 2020 Results - Earnings Call Transcript

CorMedix (CRMD) delivered earnings and revenue surprises of 8.70% and -48.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Reports Q1 Loss, Misses Revenue Estimates

BERKELEY HEIGHTS, N.J., May  11, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American:  CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has appointed Matt David, M.D. as the Company’s Executive Vice President and Chief Financial Officer.  Dr. David will participate in the Company’s Conference Call discussing its First Quarter 2020 financial results and recent corporate developments today at 4:30pm Eastern time.

CorMedix Inc. Announces Appointment of Chief Financial Officer

BERKELEY HEIGHTS, N.J., April  23, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has entered into a new three-year Employment Agreement with Jack Armstrong, currently Executive Vice President and Head of Technical Operations. The new agreement terminates in April 2023, and may be extended annually thereafter upon mutual agreement. The Employment Agreement was concluded as CorMedix works to secure marketing authorization for Neutrolin® in the second half of 2020 with potential commercial launch in the U.S. in 2021.

CorMedix Inc. Announces Contract Extension of Jack Armstrong as Executive Vice President and Head of Technical Operations

Ardmore Shipping

Arcimoto

Ovid Therapeutics

Top Ranked Momentum Stocks to Buy for April 22nd

BERKELEY HEIGHTS, N.J., April  22, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed the previously announced sale of $5.5 million of the total $6.0 million of its available tax benefits to an unrelated, profitable New Jersey corporation through the New Jersey Economic Development Authority’s New Jersey Technology Business Tax Certificate Transfer program for State Fiscal Year 2019. As a result, the Company has received approximately $5.2 million in cash from the sale of these NOL tax benefits.

CorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program

As of late, it has definitely been a great time to be an investor CorMedix

Will CorMedix Continue to Surge Higher?

CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q4 2019 Results - Earnings Call Transcript

CorMedix (CRMD) delivered earnings and revenue surprises of 12.50% and -73.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Reports Q4 Loss, Misses Revenue Estimates

BERKELEY HEIGHTS, N.J., Feb.  03, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been approved by the New Jersey Economic Development Authority (NJEDA) to transfer approximately $5.5 million of the total $6.0 million of its available tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company’s application to participate in the New Jersey Technology Business Tax Certificate Transfer (NOL) program for State Fiscal Year 2019.  The Company anticipates receiving approximately $5.2 million in cash proceeds from the sale of its NOLs during the first quarter of 2020.  Closing is subject to NJEDA’s typical closing conditions, which are in process.

CorMedix Approved to Sell $5.5 Million of NOL Tax Benefits Through the New Jersey Economic Development Authority Program

BERKELEY HEIGHTS, N.J., Feb.  03, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the US Food and Drug Administration has granted the request for a rolling review of the New Drug Application (NDA) for Neutrolin® for the prevention of catheter-related blood stream infections (CRBSIs) in hemodialysis patients.  Neutrolin has received Fast Track Designation from FDA and the Company confirmed with FDA in a pre-NDA meeting that it was eligible to request a rolling review.  A rolling submission of the NDA is designed to expedite the review process for products being developed to address an unmet medical need.  CorMedix remains on schedule for a potential NDA approval during the second half of 2020.

CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application

CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q3 2019 Results - Earnings Call Transcript

CorMedix (CRMD) delivered earnings and revenue surprises of 12.00% and -68.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Reports Q3 Loss, Misses Revenue Estimates

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time

CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., Nov.  06, 2019  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the Company and Robert Cook, the Chief Financial Officer of the Company, have mutually agreed not to renew his employment agreement, which expires on January 31, 2020.  Mr. Cook will assist the Company in transitioning his responsibilities.

CorMedix Inc. Announces a Change to its Senior Leadership

Pre-NDA Meeting Scheduled Pre-NDA Meeting Scheduled

CorMedix Completes Successful CMC Interaction with the FDA

BERKELEY HEIGHTS, N.J., Sept.  26, 2019  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will present a corporate overview at the Cantor 2019 Global Healthcare Conference.

CorMedix Inc. to Present at the Cantor 2019 Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept.  26, 2019  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that as part of its continuing efforts to simplify its capital structure, the Company agreed to reduce the exercise price on 1.2 million of its Series B Warrants expiring August 2022 from the current exercise price of $5.25 to $4.00 in return for their immediate exercise.  The transaction has closed, resulting in proceeds to the Company of approximately $4.9 million. 

CorMedix Inc. Announces Exercises of Outstanding Warrants

CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q2 2019 Results - Earnings Call Transcript

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for CorMedix Stock (CRMD)